These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22241725)

  • 21. Polish experience in Peptide receptor radionuclide therapy.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
    Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.
    Soeiro P; Martins H; Silva R; Moreira AP
    BMJ Case Rep; 2020 Mar; 13(3):. PubMed ID: 32234855
    [No Abstract]   [Full Text] [Related]  

  • 23. [Neuroendocrine tumor therapy (NETTER-1) trial:
    Derlin T
    Radiologe; 2017 May; 57(5):343-345. PubMed ID: 28184947
    [No Abstract]   [Full Text] [Related]  

  • 24. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of kidney volume estimation on dosimetry in lutetium-177 DOTATATE therapy.
    Matthews LF; Jones IW
    Nucl Med Commun; 2018 Jun; 39(6):527-532. PubMed ID: 29528911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.
    Kairemo K; Kangasmäki A
    Recent Results Cancer Res; 2013; 194():537-50. PubMed ID: 22918781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy With
    Kendi AT; Halfdanarson TR; Packard A; Dundar A; Subramaniam RM
    AJR Am J Roentgenol; 2019 Aug; 213(2):309-317. PubMed ID: 31039017
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination therapy of 177Lu and 90Y Dotatate for treatment of neuroendocrine cancer.
    Ashton CE; Jeans SP; Valle JW
    Nucl Med Commun; 2014 Jun; 35(6):585-7. PubMed ID: 24556965
    [No Abstract]   [Full Text] [Related]  

  • 29. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The next generation of peptide receptor radionuclide therapy.
    Brabander T; Nonnekens J; Hofland J
    Endocr Relat Cancer; 2019 Aug; 26(8):C7-C11. PubMed ID: 31200364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist
    Reidy-Lagunes D; Pandit-Taskar N; O'Donoghue JA; Krebs S; Staton KD; Lyashchenko SK; Lewis JS; Raj N; Gönen M; Lohrmann C; Bodei L; Weber WA
    Clin Cancer Res; 2019 Dec; 25(23):6939-6947. PubMed ID: 31439583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptide receptor radionuclide therapy for metastatic paragangliomas.
    Pinato DJ; Black JR; Ramaswami R; Tan TM; Adjogatse D; Sharma R
    Med Oncol; 2016 May; 33(5):47. PubMed ID: 27059363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
    Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
    Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supportive measures and finer practice points in 177Lu-DOTATATE PRRT for NET: aiming for optimal disease management.
    Basu S; Ostwal V; Ranade R; Panda D
    J Nucl Med; 2014 Nov; 55(11):1916-7. PubMed ID: 25214639
    [No Abstract]   [Full Text] [Related]  

  • 37. Section Editor's Notebook:
    Subramaniam RM
    AJR Am J Roentgenol; 2018 Aug; 211(2):244-245. PubMed ID: 30036089
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis.
    Yordanova A; Mayer K; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Dec; 41(12):977-979. PubMed ID: 27749410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of targeted antisense 177Lu radiotherapy.
    Balkin ER; Jia F; Miller WH; Lewis MR
    Anticancer Res; 2011 Oct; 31(10):3143-9. PubMed ID: 21965720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kidney dosimetry during
    Sandström M; Garske-Román U; Johansson S; Granberg D; Sundin A; Freedman N
    Acta Oncol; 2018 Apr; 57(4):516-521. PubMed ID: 28920501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.